Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Retrospective study comparing survival when ipilimimab used with and without radiotherapy in patients with advanced melanoma.
Authors
Dominique Siobhan Parslow
Tayside health trust, Shields, Tyne and Wear, United Kingdom
Dominique Siobhan Parslow, Toby Laurence James Talbot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Antagonists Targeting T-cell Checkpoints
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 83)
DOI
10.1200/JCO.2017.35.7_suppl.83
Abstract #
83
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Comparing the cost-effectiveness of immunotherapy strategies in BRAF wild-type advanced melanoma.
First Author: Simon B. Zeichner
Poster
2013 ASCO Annual Meeting
Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?
First Author: Joanna Mangana
Poster
2022 ASCO Annual Meeting
Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
First Author: F. Stephen Hodi
Poster
2021 ASCO Annual Meeting
BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.
First Author: Olivier Jules van Not